2-AG as a potential biomarker for predicting response to short-term fluoxetine treatment in a mouse model of depression
Major depressive disorder (MDD) is a complex psychiatric condition with significant individual and social impact and marked variability in treatment response. Identifying biomarkers that predict antidepressant efficacy remains a major challenge, and metabolomic approaches offer a powerful tool to uncover biochemical changes associated with depression and treatment outcome. The prefrontal cortex and the hippocampus are key brain regions involved in the pathophysiology of MDD and antidepressant response. Fluoxetine, one of the most commonly prescribed antidepressants, influences not only serotonergic signaling but also the endocannabinoid system. Accordingly, evaluating endocannabinoid levels might provide critical insight into their contribution and the effect of fluoxetine. To identify biomarkers associated with early antidepressant response, male mice were exposed for 5 weeks to the chronic unpredictable mild stress (CUMS) protocol, with fluoxetine treatment administered during the final week. Liquid chromatography-tandem mass spectrometry analyses of hippocampal and prefrontal cortex samples revealed that behavioral improvement following short-term fluoxetine treatment was accompanied by increased hippocampal 2-arachidonoylglycerol (2-AG), along with reduced GABA and glutamate levels in the prefrontal cortex. These findings suggest that increased 2-AG levels may predict early response to fluoxetine.
Authors
- Rafael J. Maldonado (ORCID: https://orcid.org/0000-0002-4359-8773)
- Miquel Martín (ORCID: https://orcid.org/0000-0001-7771-611X)
- Beltrán Álvarez-Pérez (ORCID: https://orcid.org/0000-0001-8033-3136)
- Victor Gorgievski
- El Chérif Ibrahim (ORCID: https://orcid.org/0000-0003-3973-7862)
- Eleni T. Tzavara
- Patricia Robledo (ORCID: https://orcid.org/0000-0002-7941-0939)
- Andrea Rodríguez-López (ORCID: https://orcid.org/0009-0001-9576-7129)
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Universitat Autònoma de Barcelona (ES)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Universitat Pompeu Fabra (ES)
- Université Paris Cité (FR)
- Aix-Marseille Université (FR)
- Barcelona Biomedical Research Park (ES)
- Assistance Publique Hôpitaux de Marseille (FR)
- Toxicologie, Pharmacologie et Signalisation Cellulaire (FR)
- Hospital Del Mar (ES)
- Hôpital Sainte-Marguerite (FR)
- Municipal Institute for Medical Research (ES)
- Institut de Neurosciences de la Timone (FR)
- Hospital del Mar Research Institute (ES)
- Neuroscience et Psychiatrie Translationnelle de Strasbourg (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Translational Psychiatry
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41398-026-04548-8
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Agence Nationale de la Recherche
- Generalitat de Catalunya
- Institució Catalana de Recerca i Estudis Avançats
- Ministerio de Sanidad, Servicios Sociales e Igualdad
- Ministerio de Ciencia e Innovación
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- Departament d'Universitats, Recerca i Societat de la Informació
- Agencia Estatal de Investigación